New Hampshire Patent of the Month – April 2023
ImmuNext Inc, a biopharmaceutical company, has recently patented their immunosuppression methodologies which lead to an improved anti-CD154 antibody. The improved antibody has lower toxicity and improved functional properties, making it useful in the treatment of inflammatory disorders, allergies and more.
Anti-CD154 antibodies have been used in immune therapies for years, but they come with certain limitations such as toxicity and the potential for clotting reactions in patients. ImmuNext’s methods address these issues by providing high-affinity antibodies that do not elicit such adverse reactions. These antibodies can be used to treat a range of disorders including inflammatory disorders, allergies, autoimmunity, transplant, and cancers.
ImmuNext’s invention potential applications are vast, including the treatment of conditions mediated by CD40 signaling. This could provide a breakthrough in treating disorders such as Crohn’s disease, rheumatoid arthritis, and systemic lupus erythematosus, among others. Additionally, the invention includes the administration of a cell, antigen, tissue, organ, or biologic against which prolonged immunosuppression is to be elicited. This opens up a new avenue for treatment, especially in the context of transplant and cancer therapies.
ImmuNext’s invention is a promising development in the field of immune therapies. It provides a safer and more effective option for treating a range of disorders. As research in this area continues, it is exciting to consider the possibilities that could emerge from ImmuNext’s groundbreaking work.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
